Moderna’s Final Covid Vaccine Results Are Imminent. Billions in Revenue Will Follow, Goldman Says.

Bill Alpert

The biotech firm will go from no product sales to more than $13 billion next year, writes Goldman Sachs’ Salveen Richter. She’s raising her price target for the stock to $139 from $107.